Reduced Q2 revenue projections lead to a decline in RxSight's stock value.
In a surprising turn of events, shares of medical technology company RxSight (NASDAQ: RXST) plummeted by 28% after announcing its preliminary second-quarter 2025 revenue and revised full-year guidance.
Despite a 28% increase in revenue in the first quarter of 2025 compared to the same period in 2024, the company's second-quarter revenue stood at approximately $33.6 million, representing a 4% decrease from the prior-year period and an 11% decrease from the first quarter. This decline in revenue was a significant concern for investors.
Moreover, RxSight revised its full-year 2025 revenue guidance downward to between $120 million and $130 million, a substantial reduction from the previous range of $160 million to $175 million. This downward revision represents a year-over-year reduction of 14% to 7%.
One of the key factors contributing to the revenue decline and the subsequent stock drop was the weak sales of Light Delivery Devices (LDDs). The company reported selling only 40 units in the second quarter, a 49% decrease from the same period last year and a 45% decrease from the previous quarter.
The revised outlook and weak sales figures have raised concerns about RxSight's commercial strategy and its ability to meet its initial revenue projections. As a result, the stock market reacted negatively, with RxSight's stock plummeting after the announcement.
It is worth noting that the second-quarter consensus revenue estimate stands at $39.78 million, a 14.02% year-over-year increase. However, the company's actual revenue fell short of this estimate.
Looking ahead, RxSight expects to announce its second-quarter financial results on Thursday, August 7. The company's operating expense is estimated to be in the range of $145M to $155M, and the 2025 gross margin is anticipated to be in the range of 72% to 74%.
Despite the current challenges, RxSight's CEO, Ron Kurtz, stated that the company is evolving its commercial approach to re-direct more focus toward supporting customer success within new and existing practices. This shift is expected to result in an implied increase of 130 basis points to 330 basis points compared to 2024.
Post market, shares of RxSight were down 23.85% to $9.74. Despite the stock drop, RxSight's cash, cash equivalents and short-term investments as of June 30 are estimated to be $227.5 million, providing the company with a strong financial position to navigate through these challenging times.
In light of the revised financial outlook and weak sales figures, investors might reconsider their investment in the business sector, particularly in medical technology companies like RxSight. The declining stock value could signal a need for strategic financial management to address the company's commercial challenges and meet revenue projections.
